Raymond James Financial Services Advisors, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 15,494 shares of APLS stock, worth $386,110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,494
Previous 14,446
7.25%
Holding current value
$386,110
Previous $554,000
19.49%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding APLS
# of Institutions
296Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$305 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$296 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$253 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$243 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$224 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.74B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...